Published in Clin Pharmacol Ther on February 28, 2007
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood (2014) 1.63
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost (2008) 1.51
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics (2009) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med (2007) 1.26
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics (2007) 1.12
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009) 1.02
Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate. Stat Interface (2011) 1.01
Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol (2010) 0.96
High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics (2011) 0.95
Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol (2013) 0.93
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet (2011) 0.90
Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother (2008) 0.88
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88
Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol (2011) 0.83
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels (2010) 0.80
VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol (2008) 0.80
Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. Eur J Clin Pharmacol (2011) 0.80
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy (2016) 0.78
Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiol Drug Saf (2014) 0.77
Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiol Drug Saf (2016) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. BMC Genet (2016) 0.75
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75
Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease? Wien Klin Wochenschr (2009) 0.75
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther (2012) 6.92
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes. Nature (1999) 5.85
Adjustments for center in multicenter studies: an overview. Ann Intern Med (2001) 5.28
Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem (1999) 4.94
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Noninvasive imaging of in vivo blood flow velocity using optical Doppler tomography. Opt Lett (1997) 4.48
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Phase-resolved optical coherence tomography and optical Doppler tomography for imaging blood flow in human skin with fast scanning speed and high velocity sensitivity. Opt Lett (2000) 4.33
neurogenin1 is essential for the determination of neuronal precursors for proximal cranial sensory ganglia. Neuron (1998) 4.25
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A (1995) 4.16
DNA sequence and comparative analysis of chimpanzee chromosome 22. Nature (2004) 4.12
The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development (1999) 3.74
Reamed or unreamed nailing for closed tibial fractures. A prospective study in Tscherne C1 fractures. J Bone Joint Surg Br (1996) 3.71
The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development (1991) 3.67
Light control of Arabidopsis development entails coordinated regulation of genome expression and cellular pathways. Plant Cell (2001) 3.60
Y-Chromosome evidence for a northward migration of modern humans into Eastern Asia during the last Ice Age. Am J Hum Genet (1999) 3.60
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med (1993) 3.55
Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicol Sci (2000) 3.45
Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science (1999) 3.40
The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM (1996) 3.31
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature (1997) 3.26
The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today (1994) 3.13
Genetically engineered Saccharomyces yeast capable of effective cofermentation of glucose and xylose. Appl Environ Microbiol (1998) 3.05
Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J (1990) 2.97
Effect of trends on detrended fluctuation analysis. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 2.95
Evidence for an important role of WRKY DNA binding proteins in the regulation of NPR1 gene expression. Plant Cell (2001) 2.90
Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br (1998) 2.82
Positional cloning of the mouse saccharin preference (Sac) locus. Chem Senses (2001) 2.75
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Dosimetric effects of needle divergence in prostate seed implant using 125I and 103Pd radioactive seeds. Med Phys (2000) 2.67
A genetic analysis of neural progenitor differentiation. Neuron (2001) 2.66
Dual bidirectional promoters at the mouse dhfr locus: cloning and characterization of two mRNA classes of the divergently transcribed Rep-1 gene. Mol Cell Biol (1989) 2.66
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res (2001) 2.65
Optical Doppler tomographic imaging of fluid flow velocity in highly scattering media. Opt Lett (1997) 2.64
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
Modulation of Ca(2+) entry by polypeptides of the inositol 1,4, 5-trisphosphate receptor (IP3R) that bind transient receptor potential (TRP): evidence for roles of TRP and IP3R in store depletion-activated Ca(2+) entry. Proc Natl Acad Sci U S A (1999) 2.52
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
Fire and flood management of coastal swamp enabled first rice paddy cultivation in east China. Nature (2007) 2.36
Acute compartment syndrome in tibial diaphyseal fractures. J Bone Joint Surg Br (1996) 2.34
The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol (2001) 2.32
Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med (2000) 2.31
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol (2005) 2.30
Glass abuse and urban licensed premises. J R Soc Med (1990) 2.28
Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study. Osteoporos Int (2008) 2.27
Molecular map of the murine S region. Proc Natl Acad Sci U S A (1983) 2.24
A radiation hybrid map of the cat genome: implications for comparative mapping. Genome Res (2000) 2.22
Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res (2000) 2.21
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem (2000) 2.19
Anticipation of the difficult airway: preoperative airway assessment, an educational and quality improvement tool. Br J Anaesth (2013) 2.18
Surveillance of the first case of human avian influenza A (H7N9) virus in Beijing, China. Infection (2013) 2.18
Selective serotonin reuptake inhibitors and myocardial infarction. Circulation (2001) 2.14
Two inducers of plant defense responses, 2,6-dichloroisonicotinec acid and salicylic acid, inhibit catalase activity in tobacco. Proc Natl Acad Sci U S A (1995) 2.14
Effects of environmental antiandrogens on reproductive development in experimental animals. Hum Reprod Update (2001) 2.14
Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet (1997) 2.10
Structure of a diubiquitin conjugate and a model for interaction with ubiquitin conjugating enzyme (E2). J Biol Chem (1992) 2.08
C1 inhibitor deficiency: consensus document. Clin Exp Immunol (2005) 2.07
Doppler standard deviation imaging for clinical monitoring of in vivo human skin blood flow. Opt Lett (2000) 2.07
The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis (2001) 2.06
Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand J Rheumatol (2008) 2.06
Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem (1995) 2.05
Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol (1999) 2.02
Identification of genes encoding receptor-like protein kinases as possible targets of pathogen- and salicylic acid-induced WRKY DNA-binding proteins in Arabidopsis. Plant J (2000) 2.01
Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. J Clin Invest (1986) 2.00
Assignment of the structural gene for the third component of human complement to chromosome 19. Proc Natl Acad Sci U S A (1982) 2.00
Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med (1991) 1.99
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Prevalence of Staphylococcus aureus carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China. Clin Microbiol Infect (2008) 1.95
Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol (1997) 1.94
The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet (1999) 1.94
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
Human lumbar vertebrae. Quantitative three-dimensional anatomy. Spine (Phila Pa 1976) (1992) 1.92
Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A (2001) 1.91
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci (1998) 1.90
Isolation and characterization of two pathogen- and salicylic acid-induced genes encoding WRKY DNA-binding proteins from tobacco. Plant Mol Biol (2000) 1.89
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol (2001) 1.87